胰腺癌的[18F]F-AlF-NOTA-FAPI-04正电子发射断层显像/计算机断层显像(PET/CT)成像:分布模式与治疗意义
前瞻性研究纳入103例未经治疗的癌症患者(胰腺癌36例、非胰腺癌67例),行[18F]F-AlF-NOTA-FAPI-04 PET/CT。胰腺癌SUVmax、SUVmean及TLF均显著高于非胰腺肿瘤(均P<0.001);胰头/颈部肿瘤摄取高于体/尾部(SUVmean P=0.016)。部分肝细胞癌患者可见轻中度胰腺摄取,部分与碱性磷酸酶升高相关。
要点
- 胰腺癌SUVmax 16.3±4.4、SUVmean 6.3±2.3、TLF 321.5±251.3,均显著高于非胰腺肿瘤。
- 胰头/颈部胰腺癌SUVmean 7.7±3.1,高于体/尾部6.3±2.9(P=0.016)。
- 非胰腺恶性肿瘤患者可出现轻中度胰腺生理性或非特异性摄取,需仔细鉴别。
核心结论
- [18F]F-AlF-NOTA-FAPI-04 PET/CT对胰腺导管腺癌显示高特异性,尤其在头/颈部肿瘤;非胰腺恶性肿瘤中的生理性或非特异性胰腺摄取需仔细判读以避免误诊。
研究设计与样本
- 前瞻性研究,纳入103例未经治疗的癌症患者(胰腺癌36例、非胰腺癌67例),行[18F]AlF-NOTA-FAPI-04 PET/CT,分析MTV、SUV及TLF。
关键影像表现/征象
- 胰腺癌SUVmax 16.3±4.4,非胰腺肿瘤5.0±4.3,P<0.001。
- 胰腺癌SUVmean 6.3±2.3,非胰腺肿瘤1.7±1.2,P<0.001。
- 胰腺癌TLF 321.5±251.3,非胰腺肿瘤89.4±62.1,P<0.001。
- 胰头/颈部肿瘤SUVmean 7.7±3.1,体/尾部6.3±2.9,P=0.016。
- 部分肝细胞癌患者可见轻中度胰腺摄取,部分与碱性磷酸酶升高相关。
诊断标准与关键数值
- TLF与肿瘤大小及分期正相关(F=2.576,P=0.027)。
- 胰腺癌诊断性能以SUVmax、SUVmean、TLF与非胰腺肿瘤比较评估,原文未报告敏感度、特异度、AUC及阈值。
临床应用与阅片要点
- 判读时注意胰腺癌SUVmax、SUVmean及TLF均显著高于非胰腺肿瘤。
- 胰头/颈部病变摄取高于体/尾部,阅片时结合部位评估。
- 非胰腺恶性肿瘤患者出现胰腺轻中度摄取时,需鉴别生理性或非特异性摄取,避免误诊。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: This study aimed to evaluate the diagnostic performance of [18F]F-AlF-NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) in pancreatic cancer by comparing its uptake patterns with other tumour types and analysing intrapancreatic heterogeneity. The study also explored possible causes of physiological pancreatic uptake to aid in distinguishing non-malignant uptake from true pathological lesions and improve diagnostic accuracy.
MATERIALS AND METHODS: In this prospective study, 103 treatment-naïve cancer patients (36 pancreatic, 67 nonpancreatic) underwent [18F] AlF-NOTA-FAPI-04 PET/CT. Metabolic tumour volume (MTV), standardised uptake values (SUV), and total lesion Fibroblast Activation Protein (FAP) expression (TLF) were analysed. Hierarchical regression and independent t-tests were applied to assess correlations between imaging features and clinicopathological characteristics.
RESULTS: Pancreatic cancer exhibited significantly higher SUVmax (16.3 ± 4.4 vs 5.0 ± 4.3, P<0.001), SUVmean (6.3 ± 2.3 vs 1.7 ± 1.2, P<0.001), and TLF (321.5 ± 251.3 vs 89.4 ± 62.1, P<0.001) compared to non-pancreatic tumors. Tumours in the pancreatic head/neck region demonstrated greater [68 G]G-FAPI-04 uptake than body/tail lesions (SUVmean: 7.7 ± 3.1 vs 6.3 ± 2.9, P=0.016). TLF correlated positively with tumour size and stage (F = 2.576, P=0.027). Mild to moderate pancreatic uptake was also observed in a subset of patients with hepatocellular carcinoma, partially correlating with elevated alkaline phosphatase (ALP) levels.
CONCLUSION: [18F]F-AlF-NOTA-FAPI-04 PET/CT shows high specificity for pancreatic ductal adenocarcinoma, particularly in head/neck tumours. Physiological or nonspecific pancreatic uptake in nonpancreatic malignancies warrants careful interpretation to avoid misdiagnosis.
引用
- Wang C, Zhu Z, Xu L, et al. Imaging pancreatic cancer with [18F]F-AlF-NOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT): distribution patterns and therapeutic implications. Clin Radiol. 2025. PMID: 40513531. doi:10.1016/j.crad.2025.106954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。